Investigational drug · Phase 3
NH002
Also called: Perflutren Lipid Microspheres
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cardiac Diseases.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "NH002"
First trial start
2025
Mar 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NH002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cardiac Diseases
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "NH002" as an intervention, largest first.
- A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac EchocardiographyPivotal-lookingNot yet recruiting
Trust Bio-sonics, Inc.Industry
NCT07740421 · 150 participants (planned) · Start Jul 2026 · Primary completion Jul 2027
Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension · For: Cardiac Diseases
- Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac EchocardiographyPivotal-lookingActive, not recruiting
Trust Bio-sonics, Inc.Industry
NCT06815627 · 150 participants (planned) · Start Mar 18, 2025 · Primary completion Feb 2027
Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension · For: Cardiac Diseases
Sites: Keelung, Taiwan; Taichung, Taiwan; Taipei, Taiwan · 6 sites in all
Trust Bio-sonics, Inc.Industry
NCT04185246 · 36 participants · Start Nov 4, 2019 · Primary completion Jul 1, 2020
Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension · For: Cardiac Disease
Sites: Taipei, Taiwan · 2 sites in all
National Taiwan University HospitalAcademic, hospital or other
NCT07314385 · 24 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2027
Drug: nanoliposomal irinotecan+5-FU+leucovorin; NH002 (Perflutren Lipid Microspheres) Injectable Suspension · For: Pancreatic Adenocarcinoma Metastatic; Liver Metastasis
Sites: Taipei, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical Studies of MVT-100, A Novel Ultrasound Enhancing Agent.
Meuillet EJ, Lusk J, Tadevich H, et al. · Ultrasound Med Biol 2027
- Cardiac Arrest From Sulfur Hexafluoride Contrast Anaphylaxis After Prior Perflutren Hypersensitivity.
Corsi DR, Simon C, Nagella N, et al. · JACC Case Rep 2026
- Perflutren lipid microspheres for echocardiogram contrast: a clinical case of anaphylaxis not caused by PEG.
Wang C, Campbell J, Lea-Banks H, et al. · Allergy Asthma Clin Immunol 2025
- Power-Doppler-based NH002 microbubble sonoporation with chemotherapy relieves hypoxia and enhances the efficacy of chemotherapy and immunotherapy for pancreatic tumors.
Wu SY, Wang CH, Kang ST, et al. · Sci Rep 2024
- Contrast-Enhanced Ultrasound in Small Intestinal Ischemia: Proof of Concept.
Gummadi S, Koenig G, Wessner CE, et al. · J Ultrasound Med 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.